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Abstract Age-related macular degeneration (AMD) is a leading cause of blindness
in people aged ‡50 years. Wet AMD in particular has a major impact on
patient quality of life and imposes substantial burdens on healthcare systems.
This systematic review examined the cost-effectiveness data for current
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therapeutic options for wet AMD. PubMed and EMBASE databases were
searched for all articles reporting original cost-effectiveness analyses of wet
AMD treatments. The Centre for Reviews and Dissemination and Cochrane
Library databases were searched for all wet AMD health technology assess-
ments (HTAs). Overall, 44 publications were evaluated in full and included in
this review.
A broad range of cost-effectiveness analyses were identified for the most
commonly used therapies for wet AMD (pegaptanib, ranibizumab and photo-
dynamic therapy [PDT] with verteporfin). Three studies evaluated the cost
effectiveness of bevacizumab in wet AMD. A small number of analyses of
other treatments, such as laser photocoagulation and antioxidant vitamins,
were also found.
Ranibizumab was consistently shown to be cost effective for wet AMD in
comparison with all the approved wet AMD therapies (four of the five studies
identified showed ranibizumab was cost effective vs usual care, PDT or pe-
gaptanib); however, there was considerable variation in the methodology for
cost-effectiveness modelling between studies. Findings from the HTAs sup-
ported those from the PubMed and EMBASE searches; of the seven HTAs
that included ranibizumab, six (including HTAs for Australia, Canada and the
UK) concluded that ranibizumab was cost effective for the treatment of wet
AMD;most compared ranibizumabwith PDT and/or pegaptanib. By contrast,
HTAs at best generally recommended pegaptanib or PDT for restricted use in
subsets of patients with wet AMD. In the literature analyses, pegaptanib was
found to be cost effective versus usual/best supportive care (including PDT) or
no treatment in one of five studies; the other four studies found pegaptanib was
of borderline cost effectiveness depending on the stage of disease and time
horizon. PDT was shown to be cost effective versus usual/best supportive care
or no treatment in five of nine studies; two studies showed that PDT was of
borderline cost effectiveness depending on baseline visual acuity, and two
showed that PDT was not cost effective. We identified no robust studies that
properly evaluated the cost effectiveness of bevacizumab in wet AMD.
Age-related macular degeneration (AMD)/age-
related maculopathy (ARM) refers to pathologi-
cal changes in the central area of the retina that
can occur in people aged ‡50 years.[1] Many people
who have these changes do not experience symp-
toms; however, progressive alterations can lead
to late-stage ARM (this stage is then referred to
as AMD) and vision loss. The form of late-stage
AMDmost likely to cause blindness is neovascular
exudative disease (also termed wet AMD).[2] Wet
AMD can be designated classic or occult accord-
ing to its features on fluorescein angiography,
with AMD lesions classified as either 100% clas-
sic, predominantly classic (in which choroidal
neovascularization [CNV] accounts for at least
50% of the lesion), minimally classic (where CNV
accounts for part of but <50% of the lesion) or
occult (where there is no CNV).[2]
Symptoms of wet AMD often begin with cen-
tral visual blurring, distortion (metamorphopsia)
or a dark central patch (scotoma), although, if
only one eye is affected, these features may not be
noticed for some time. When the second eye be-
comes affected, patients suddenly lose the ability
to read, drive or see fine details such as facial
expressions and features. AMD (both wet and
dry) is one of the leading causes of blindness in
the Western world and, because AMD affects
older people, its prevalence is set to increase with
the rising average age of populations. Indeed, it
has been estimated that by 2020 the prevalence of
AMD will be three times greater than it was in
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1995, with up to 7.5million people aged >65 years
likely to be affected by AMD-related visual
impairment.[3]
Costs associated with visual impairment are
considerable, and include medical care, loss of
income and paid home help. A 2006 study in
France[4] estimated that total country-wide non-
medical costs of visual impairment were h9800
million per annum. A similar study in Australia[5]
estimated that the 2004 cost for vision disorders
was Australian dollars ($A)9850million. A further
study estimated total annual non-medical costs of
visual impairment to be h10 749million, h9214
million, h12 069million and h15 180million in
France, Germany, Italy and the UK, respectively
(year 2004 values).[6]
The most commonly used current treatment
options for wet AMD are laser photocoagulation,
photodynamic therapy (PDT) and intravitreal
injections with inhibitors of vascular endothelial
growth factor (VEGF)-A. Laser photocoagula-
tion aims to prevent further vision loss by de-
stroying the neovascular complex; PDT is based
on a similar concept but involves using a photo-
sensitive agent (usually verteporfin), given intra-
venously. This agent is activated by laser light
(689 nm wavelength) directed to the CNV lesion
and causes damage to vascular endothelial cells and
thrombotic occlusion of the blood vessels, while
reducing concurrent damage to the overlying
retina. New pharmaceutical treatments approved
for wet AMD are directed against VEGF-A; for
example, ranibizumab (a monoclonal antibody
fragment) and pegaptanib (a synthetic oligonu-
cleotide) inhibit the biological activity of VEGF-A,
thereby aiming to reduce angiogenesis and stall
AMD progression.[7-9]
Anti-VEGF treatments for wet AMD have
recently been the subject of intense scrutiny; al-
though they have revolutionized the treatment of
the condition, offering increases in visual acuity
over traditional therapies in the majority of pa-
tients, they come at increased costs. Several eco-
nomic analyses have thus been conducted by both
health economists and ophthalmologists to eval-
uate the cost effectiveness of wet AMD treat-
ments; in addition, because of the implications
for medical and social care, healthcare authorities
around the world have commissioned their own
health technology assessments (HTAs). The aim
of this review is to examine the available cost-
effectiveness data for the current therapeutic op-
tions for wet AMD by conducting a systematic
search of the scientific literature and reimburse-
ment authority-authorized HTAs.
1. Literature Review
1.1 Methods
A search of the PubMed and EMBASE data-
bases was conducted in November 2009 using the
following search terms: (i) macular degenera-
tion[MeSH] AND (cost-benefit analysis[MeSH]
OR economics[MeSH]); (ii) [wet OR neovascular]
AND ‘macular degeneration’ AND cost. No other
limits were imposed on the search. All articles
published before or during November 2009 were
eligible for screening. Titles and abstracts of all
articles were screened by two reviewers.
In addition, the HTA databases and UKNHS
Economic Evaluation Databases (EED) at the
Centre for Reviews and Dissemination (CRD),
University of York, and the Cochrane Library
were searched in May 2010 to identify HTAs
using the following search terms: (Macula OR
Macular OR Retina OR Retinal OR Subretinal
ORChoroidal ORAMDORARMD). All HTAs
published before or during May 2010 were eligi-
ble for screening. The titles and/or abstracts of all
identified records were screened manually by two
reviewers for potential inclusion in the review.
The full texts of the identified publications
were obtained and screened manually to select
those that contained novel cost-effectiveness as-
sessments, and those that were full HTAs (re-
gardless of whether the HTAs contained original
cost-effectiveness assessments). Data from pub-
lications that met these criteria were extracted
into the tables included in this review. Studies
that reported purely cost data (e.g. burden-of-
illness studies, cost-of-illness studies) or that were
reviews of previous cost-effectiveness evaluations,
were excluded. Where possible, foreign language
publications were translated in order to gather
the required information.
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1.2 Results
The flow of the systematic review process is
presented in figure 1. In total, 843 publications were
identified by searching the PubMed, EMBASE,
CRD and Cochrane Library databases. After
eliminating duplicates, 351 unique publications
were identified, and 75 warranted further investi-
gation. Of the 276 articles excluded based on the
title/abstract, most were not cost-effectiveness
studies/HTAs of wet AMD treatments. The re-
mainder were opinion, comment or letter articles,
review articles, foreign language publications with
no translation, or did not contain any pharma-
coeconomic data.
The studies identified in our analysis employed
a broad range of methodologies, perspectives and
assumptions, which made comparisons between
studies difficult. A summary of the studies is pro-
vided in the Supplemental Digital Content 1,
http://links.adisonline.com/PCZ/A100.Most stud-
ies expressed the results in terms of cost per
QALY gained (i.e. most studies involved cost-
utility analyses). Other cost-effectiveness measures
included the cost per vision-year gained, cost per
line-year gained (using either the Snellen or, mostly,
the ETDRS chart) [see table I for full study names]
and cost per case of blindness prevented. The ma-
jority of economic analyses used a second (better-
seeing) eye model. This model assumes treatment is
not initiated until the second eye is affected; effec-
tive treatment thus has a greater impact on visual
Records identified through
database searching
(n = 843)
Records after duplicates
removed
(n = 351)
Records screened
(n = 351)
Records excluded
(n = 276)
Full-text articles excluded
Journal articles:
• review paper (n = 12)
• comment or letter (n = 6)
• no economic data
presented (n = 2)
• editorial (n = 1)
HTAs:
• not a full HTA (n = 7)
• HTA published as journal
article and thus included
above (n = 3)
Full-text articles assessed
for eligibility (n = 75)
Studies included in
qualitative synthesis
(n = 44)
Fig. 1. Flow of the systematic review process. HTA =health
technology assessment.
Table I. Study acronyms and names
Study
acronym
Study name
ABC Avastin (Bevacizumab) for Choroidal neovascular age-related macular degeneration
ANCHOR ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in age-related macular
degeneration
AREDS Age-Related Eye Disease Study
CATT Comparison of Age-related macular degeneration Treatments Trial
ETDRS Early Treatment Diabetic Retinopathy Study
IVAN A randomised controlled trial of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization
MARINA Minimally classic/occult trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related macular
degeneration
MICMAC MICroeconomics of MACular degeneration
MPS Macular Photocoagulation Study
PIER Phase 3b, multi-centre, randomized, double-masked, sham Injection-controlled study of the Efficacy and safety of
Ranibizumab in subjects with subfoveal choroidal neovascularization with or without classic CNV secondary to AMD
PrONTO Prospective Optical coherence tomography imaging of patients with Neovascular AMD Treated with intra-Ocular ranibizumab
TAP Treatment of Age-related macular degeneration with Photodynamic therapy
VISION VEGF Inhibition Study In Ocular Neovascularization
AMD = age-related macular degeneration; CNV = choroidal neovascularization; VEGF = vascular endothelial growth factor.
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acuity than if the first eye to be affectedwere treated
(when the unaffected eye compensates for loss of
vision in the affected eye). Only two studies in-
cluded a first-eye model, and in both cases this was
evaluated alongside a second-eye model.
The major factors that had an impact on cost
effectiveness were the timeframes used in the
model, and the inclusion or exclusion of indirect
costs of treatment (i.e. societal costs related to
blindness, including caregiver costs). The time-
frames taken into account by the models ranged
from 1 year to a lifetime, and were generally ex-
trapolated from 1–5 years of treatment. The types
of wet AMD assessed most frequently were clas-
sic or predominantly classic AMD, but many
studies included all types of the disease. Table II
provides an overview of the methodology of the
cost-utility studies included in the review. Treat-
ment of the predominantly classic form of AMD
was typically associated with lower incremental
cost-effectiveness ratios (ICERs) than treatment
of the occult disease form.
2. Comparison of Treatments with Best
Supportive Care, Usual Care or Placebo
2.1 Laser Photocoagulation
2.1.1 Cost Utility
Laser photocoagulation was shown to be a
cost-effective treatment option for wet AMD in
the US in three studies based on data from the
MPS group. Costs per QALY gained for laser
photocoagulation compared with no treatment
or with observation were $US5629-23 176 over
time horizons of 11–14 years (table III).[10-12]
2.1.2 Other Cost-Effectiveness Measures
Data from a number of clinical trials, along
with allowable Medicare amounts for 2006, were
used to determine cost effectiveness of laser photo-
coagulation in the US by costs per Snellen line-
year gained; the cost per Snellen line-year gained
for extrafoveal disease was $US77, and for jux-
tafoveal and subfoveal disease was $US176.[32]
2.2 Photodynamic Therapy with Verteporfin
Before the availability of VEGF inhibitors for
the treatment of wet AMD, PDT was the main-
stay of therapy, and so its cost effectiveness has
been evaluated extensively. Most analyses used
efficacy data from the TAP study, a randomized
double-masked trial of 609 patients with CNV,
which showed that PDT with verteporfin could
reduce the risk of vision loss (‡15 letters) over
12 months compared with placebo.[33]
Most studies that modelled time horizons of
‡5 years have shown PDT with verteporfin to
be cost effective (<d30 000 or $US50 000–100 000
per QALY gained) compared with usual care,
placebo or routine clinical practice in Canada,
Switzerland, the UK and the US. Tables III and
IV present summaries of the cost-effectiveness
outcomes for PDT compared with usual care, no
treatment or placebo.
2.2.1 Cost Utility
Using 5-year efficacy data, the estimated cost
per QALY gained was <d30 000 in the UK over a
10-year time horizon[14] and <$US50 000 in the
US over a 12-year time horizon for predominantly
classic/classic AMD.[11,15] A Canadian HTA eval-
uated PDT from a societal perspective over an
8-year timeframe, and also judged it to be cost
effective (<$Can50 000) both for predominantly
classic CNV and for classic and occult CNV;[13]
however, Sharma et al.[19] evaluated PDT from a
third-party payer’s perspective using 1- to 2-year
TAP data and found PDT to be of poor-to-
modest cost effectiveness based on an 11-year
timeframe.
PDT was found to be more likely to be cost ef-
fective when given early in the course of the dis-
ease to patients with better visual acuity; a study
using a 7-year evaluation period in an Australian
setting[17] and a 5-year period in the UK[20] both
showed that PDT was borderline cost effective
versus placebo for patients with ‘reasonable’ in-
itial visual acuity (6/12 [20/40])1 at treatment
1 The standard definition of normal visual acuity (20/20 or 6/6 vision) is the ability to resolve a spatial pattern
separated by a visual angle of 1 minute of arc. A person with a visual acuity of 6/12 (20/40) can resolve the same
pattern at a distance of 6 metres (20 feet) as a person with ‘normal’ visual acuity can at 12 metres (40 feet).
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Table II. Summary of the methods of the reviewed cost-utility papers
Study, country, currency,
y of values
Perspective (comparator) No. of tx Annual disc.
rate (%)
Model type
Cost utility of laser photocoagulation vs UC, no tx or PL
Brown et al.,[10] US, $US, 1999 Third-party payer; 1 y of tx;
11-y timeframe (no tx)
NR 3.0 2nd eye
Brown et al.,[11] US, $US, 2005 Third-party payer – health insurance;
1 y of tx; 12-y timeframe (no tx)
1.5 over 1 y 3.0 2nd eye
Busbee et al.,[12] US, $US, 2001 Third-party payer – health insurance;
up to 5 y of tx; 14-y timeframe
(observation)
2 3.0 NR
Cost utility of PDT vs verteporfin with UC, no tx or PL
Larouche and Rochon (AETMIS –
HTA),[13] Canada, $Can, NR
Societal; 3 y of tx; 8-y timeframe (no tx) 3.4 in y 1
2.1 in y 2
1 in y 3
3.0 Combined eye
Bansback et al.,[14] UK, X, NR NR; up to 10 y of tx; 2-, 5- and 10-y
timeframes (BSC)
As per TAPa 3.5 2nd eye
Brown et al.,[11] US, $US, 2005 Third-party payer – health insurance;
12-y timeframe (no tx)
8.1 over 12 y 3.0 2nd eye
Brown et al.,[15] US, $US, 2004 Third-party payer – health insurance;
12-y timeframe (PL)
8.1 over 12 y 3.0 2nd eye
Donati,[16] Switzerland, h, NR Healthcare system; societal; 3 y of tx;
3-y timeframe (PL)
3 over 3 y 0.0 NR
Hopley et al.,[17] Australia,
$A/X, 2003
Third-party payer; 7 y of tx;
7-y timeframe (PL)
10.9 over 7 y 6.0 2nd eye
Meads et al. (HTA),[18] UK,
X, 2001
Health service and societal; 2 y of tx;
2-y timeframe (BSC)
1–8 over 2 y 0.0 2nd eye
Sharma et al.,[19] Canada,
$US, NR
Third-party payer; 2- and 11-y
timeframes (PL)
5.5 over 2 y 3.0 2nd eye
Smith et al.,[20] UK, X, 2001 Govt and tx costs only; 3 y of tx;
2- and 5-y timeframes (PL)
NR 6.0 (costs);
2.0 (benefits)
2nd eye
Cost utility of PG vs UC, no tx or PL
Brown et al.,[11] US, $US, 2005 Third-party payer – health insurance;
12 y of tx; 12-y timeframe (no tx)
18.3 over 12 y 3.0 2nd eye
Colquitt et al. (HTA),[2] UK,
X, 2005
Healthcare system and Personal
Social Services; 2 y of tx; 2- and 10-y
timeframes (UC)
9 in y 1
8 in y 2
3.5 NR
Earnshaw et al.,[21] Canada, $Can,
2004
Healthcare system; 2 y of tx; lifetime
timeframe (UC)
8.4 in y 1
6.9 in y 2
3.0 2nd eye
Javitt et al.,[22] US, $US, 2006 Third-party payer; 2 y of tx; lifetime
timeframe (PG/PDT vs PDT/UC)
8.4 in y 1
6.9 in y 2
3.0 2nd eye
Wolowacz et al.,[23] UK, X, NR UK Govt; 2 y of tx; 10-y timeframe
(BSC)
12.6 over 2 y 3.5 2nd eye
Cost utility of RB vs UC, no tx or PL
Brown et al.,[24] US, $US, 2006 Third-party payer – health insurance;
2 y of tx; 12-y timeframe (sham tx)
22 over 2 y 3.0 1st, 2nd and
combined eye
Colquitt et al. (HTA),[2] UK,
X, 2005
Healthcare system and Personal
Social Services; 1 y of tx
(predominantly classic CNV); 2 y of tx
(minimally classic CNV); 1- to 2- and
10-y timeframes (BSC)
12 over 1 y (predominantly
classic CNV); 24 over 2 y
(minimally classic CNV)
3.5 NR
Continued next page
112 Mitchell et al.
ª 2011 Adis Data Information BV. All rights reserved. Pharmacoeconomics 2011; 29 (2)
Table II. Contd
Study, country, currency,
y of values
Perspective (comparator) No. of tx Annual disc.
rate (%)
Model type
CADTH (CDR – manufacturer’s
model – HTA),[25] Canada, $Can,
2007
Third-party payer; 1 y of tx [ANCHOR
and PIER]; 2 y of tx [MARINA]; 10-y
timeframe (BSC)
ANCHOR, PIER or
MARINA regimen
5.0 2nd eye
CADTH (CDR – CADTH modelb –
HTA),[25] Canada, $Can, 2007
Third-party payer; 1 y of tx [ANCHOR
and PIER]; 2 y of tx [MARINA]; 10-y
timeframe (BSC)
ANCHOR, PIER or
MARINA regimen
NR 2nd eye
Hurley et al.,[26] US, $US, 2004 Societal; third party – healthcare
funder; 4 y of tx; 2- and 10-y
timeframes (UC)
12 in y 1
12 in y 2
4 in y 3
4 in y 4
3.0 2nd eye
Neubauer et al.,[27] Germany, h, NR Societal; 2 y of tx; 10-y timeframe
(BSC)
6 per y for 2 y 5.0 2nd eye
Between-treatment comparisons of cost utility
Brown et al. (HTA),[28] Canada,
$Can, NR
Provincial healthcare provider – direct
costs only; 2 y of tx; life expectancy
timeframe (PDT vs PG; RB vs PG)
PDT: 2 per y
PG: 8 per y
RB: 12 per y
5.0 2nd eye
Colquitt et al. (HTA),[2] UK, X,
2005
Healthcare system and Personal
Social Services; 1 y of tx; 1- to 2- and
10-y timeframes (RB vs PDT)
RB: 12 over 1 y
PDT: average no. reported
in ANCHOR
3.5 NR
CADTH (CDR – manufacturer’s
model – HTA),[25] Canada, $Can,
2007
NR; 1 y of tx (RB vs PDT) RB and PDT: ANCHOR
regimen
5.0 2nd eye
CADTH (CDR – CADTH modelb
– HTA),[25] Canada, $Can, 2007
NR; 1 y of tx; timeframe NR
(RB vs PDT)
RB and PDT: ANCHOR
regimen
5.0 2nd eye
Earnshaw et al.,[21] Canada,
$Can, 2004
Healthcare system; 2 y of tx; lifetime
timeframe (PG vs PDT)
PG: 8.4 in y 1
6.9 in y 2
PDT: 3.4 in y 1
2.2 in y 2
3.0 2nd eye
Fletcher et al.,[29] US, $US, NR Third-party payer; 2 y of tx; 2-y
timeframe (RB vs BSC; PG vs BSC;
PDT vs BSC)
RB:
(i) 12 in y 1; 12 in y 2;c
(ii) 6 in y 1; 4 in y 2;d
PG: 8.4 in y 1; 6.9 in y 2;
PDT: 3.4 in y 1; 2.2 in y 2
3.0 1st and 2nd
eye
Hernandez-Pastor et al.,[30]
Spain, h, 2007
Third-party payer; 2-y and lifetime tx;
2-y and life expectancy timeframes
(RB vs PDT)
RB: 12 per y
PDT: 2.8 in y 1
1 per y thereafter
3.0 2nd eye
Hernandez-Pastor et al.,[31]
Spain, h, 2008
Societal; lifetime tx; life expectancy
timeframe (RB vs PG)
RB: 12 per y
PG: 8 per y
3.5 2nd eye
a See table I for definitions of study acronyms.
b Assuming the Product Listing Agreement is implemented. In this agreement, the manufacturer covers the cost of ranibizumab if the patient
requires more than nine vials in year 1 or six vials in years 2 and 3 of tx.
c MARINA regimen.
d PIER regimen.
$A =Australian dollars;AETMIS =Agence D’e´valuation Des Technologies Et Des Modes D’intervention En Sante´;BSC =best supportive care;
CADTH =Canadian Agency for Drugs and Technologies in Health; CDR =Common Drug Review; CNV = choroidal neovascularization;
disc.= discount;Govt=government; HTA=health technology assessment; NR= not reported; PDT= photodynamic therapy; PG= pegaptanib;
PL= placebo; RB= ranibizumab; tx= treatment(s); UC=usual care.
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Table III. Summary of the results of the cost-utility analysesa
Study, currencyb Cost QALYs gained ICER (cost per QALY gained)
intervention comparator intervention comparator
Laser photocoagulation vs UC, no tx or PL
Brown et al.,[10] $US NR 0.186 5 629
Brown et al.,[11] $US 2 012 0.246 8 179
Busbee et al.,[12] $US 1 715 0.0740 23 176
Cost utility of PDT vs verteporfin with UC, no tx or PL
Larouche and Rochon (AETMIS – HTA),[13] $Can
Predominantly classic CNV 664 085 494 112 49 44 33 880
Classic and occult CNV 664 085 494 112 49 44 43 253
Bansback et al.,[14] X 9 381 3 491 0.773 0.702 82 329 (2 y)
15 041 9 500 1.668 1.503 33 710 (5 y)
21 246 16 600 2.550 2.329 20 996 (10 y)
Brown et al.,[11] $US 15 488 0.491 31 544
Brown et al.,[15] $US 15 277 0.491 31 013
Donati,[16] h 26 400 19 494 0.106 65 150
Hopley et al.,[17] $A/X
Initial visual acuity 6/12 (20/40) 12 478 0.395 31 607
Initial visual acuity 6/60 (20/200) 12 478 0.197 63 214
Meads et al. (HTA),[18] X 5 658 0.0311 182 188 (1 y of blindness)
4 695 0.0311 151 179 (2 y of blindness)
Sharma et al.,[19] $US
Initial visual acuity 6/12 (20/40)
Initial visual acuity 6/60 (20/200) NR
2 y, 86 721
11 y, 43 547
2 y, 173 984
11 y, 87 197
Smith et al.,[20] X
Government perspective
Visual acuity 6/12 (20/40) 6 490 1 275 1.205 1.136 75 580 (2 y)
11 700 10 200 2.375 2.205 8 823 (5 y)
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Table III. Contd
Study, currencyb Cost QALYs gained ICER (cost per QALY gained)
intervention comparator intervention comparator
Visual acuity 6/30 (20/100) 8 878 4 590 0.995 0.980 285 867 (2 y)
18 500 15 700 2.093 1.999 29 787 (5 y)
Tx costs-only perspective
Visual acuity 6/12 (20/40) 6 173 0 1.205 1.136 89 464 (2 y)
6 475 0 2.375 2.205 38 088 (5 y)
Visual acuity 6/30 (20/100) 6 173 0 0.995 0.980 411 533 (2 y)
6 475 0 2.093 1.999 68 882 (5 y)
Cost utility of PG vs UC, no tx or PL
Brown et al.,[11] $US 24 314 0.363 66 978
Colquitt et al. (HTA),[2] X 12 817 2 558 1.43 1.37 163 603 (2 y)
24 662 16 600 4.15 3.89 30 986 (10 y)
Earnshaw et al.,[21] $Can 20 016 UC, 7669 4.17 UC, 3.96 59 039
Javitt et al.,[22] $US
Early subfoveal CNV 66 638 55 108 4.75 4.44 36 282
Moderate subfoveal CNV 84 185 71 393 3.59 3.38 58 280
Late subfoveal CNV 96 771 84 400 2.86 2.77 132 381
Wolowacz et al.,[23] X 28 494 26 111 3.324 3.027 8 023
Cost utility of RB vs UC, no tx or PL
Brown et al.,[24] $US 52 652 2nd-eye model, 1.039
1st-eye model, 0.425
Combined-eye model, 0.710
2nd-eye model, 50 691
1st-eye model, 123 887
Combined-eye model, 74 169
Colquitt et al. (HTA),[2] X
Predominantly classic CNV 12 427 933 0.81 0.74 160 181 (1–2 y)
26 888 20 431 4.15 3.59 11 412 (10 y)
Minimally classic CNV or occult CNV with no classic lesions 23 902 1 541 1.54 1.40 152 464 (1–2 y)
31 096 13 787 4.79 4.10 25 098 (10 y)
CADTH (CDR – manufacturer’s model – HTA),[25] $Can
Predominantly classic CNV 79 512 74 058 5.37 5.12 21 857 (ANCHOR regimen)
75 875 72 720 5.01 4.77 12 871 (PIER regimen)
Minimally classic CNV 73 158 60 445 4.48 3.14 9 542
Occult with no classic CNV 64 864 51 158 5.93 5.57 10 345
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Table III. Contd
Study, currencyb Cost QALYs gained ICER (cost per QALY gained)
intervention comparator intervention comparator
CADTH (CDR, CADTH modelc – HTA),[25] $Can
Predominantly classic CNV
Minimally classic CNV
Occult with no classic CNV
Modified version of manufacturer’s model
26 619 (ANCHOR regimen)
21 148 (PIER regimen)
48 917
52 678
Hurley et al.,[26] $US
Including caregiver costs 78 900 42 700 0.118 308 400 (2 y)
205 800 238 300 0.68 Dominant (10 y)
Excluding caregiver costs 56 700 5 800 0.118 432 900 (2 y)
88 800 26 300 0.68 91 900 (10 y)
Neubauer et al.,[27] h
Predominantly classic CNV
Minimally classic CNV
Occult CNV
6 697
8 010
8 826
0.40
0.32
0.34
16 882
24 766
26 170
Between-treatment comparisons of cost utility
Brown et al. (HTA),[28] $Can 102 472 96 975 5.60 5.98 PG is dominant
Predominantly classic CNV 140 706 96 975 6.75 5.98 56 382
Any CNV lesion 138 733 97 569 6.72 5.98 56 194
Colquitt et al. (HTA),[2] X 12 427
26 888
4 182
21 498
0.81
4.15
0.77
3.81
202 450 (1–2 y)
15 638 (10 y)
CADTH (CDR – manufacturer’s model – HTA),[25] $Can 79 512 78 666 5.37 5.17 4 167
CADTH (CDR – CADTH modelc – HTA),[25] $Can NR NR NR NR 5 191
Earnshaw et al.,[21] $Can 20 016 15 345 4.17 3.87 49 052
Fletcher et al.,[29] $US NR
NR
NR
NR
992 103 (MARINA regimen) [RB vs BSC]
626 938 (PIER regimen) [RB vs BSC]
1 483 973 (PG vs BSC)
986 913 (PDT vs BSC)
Hernandez-Pastor et al.,[30] h 31 265
163 588
12 937
49 721
1.143
7.412
1.003
4.522
1 312 752 (2 y)
39 398 (lifetime)
Hernandez-Pastor et al.,[31] h 164 870 93 664 6.911 4.474 29 224
a See table I for definitions of study acronyms.
b See table II for details regarding the methods for each study including the year of value.
c Assuming the Product Listing Agreement is implemented. In this agreement, the manufacturer covers the cost of ranibizumab if the patient requires more than nine vials in year 1
or six vials in years 2 and 3 of tx.
$A =Australian dollars; AETMIS =Agence D’e´valuation Des Technologies Et Des Modes D’intervention En Sante´;BSC =best supportive care;CADTH =Canadian Agency for Drugs
and Technologies in Health; CDR =Common Drug Review; CNV = choroidal neovascularization; HTA = health technology assessment; ICER = incremental cost-effectiveness ratio;
NR= not reported; PDT = photodynamic therapy; PG =pegaptanib; PL = placebo; RB = ranibizumab; tx= treatment; UC = usual care.
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Table IV. Summary of the methods and results of economic evaluations using other cost-effectiveness measuresa
Study, country, currency,
y of pricing
Perspective (comparator) No. of tx Annual disc.
rate (%)
Model
type
Outcome measures and results
PDT and verteporfin vs UC, no tx or PL
Donati,[16] Switzerland, h, NR Healthcare system; societal;
3 y of tx; 3-y timeframe (PL)
3 over 3 y 0.0 NR PDT: cost per vision-y gained ranged from 8239 to 10 271
ICER ranged from 3846 to 7416
Greiner,[34] Switzerland, SwF, 1998 Societal; 6 tx in 3 y;
3-y timeframe (PL)
3 in y 1
2 in y 2
1 in y 3
NR NR PDT: cost 15 921; vision-y saved 1.068; cost per vision-y
14 907
PL: cost 10 397; vision-y saved 0.494; cost per vision-y
21 047
ICER 9624
MSAC (HTA – data from sponsor)[35]
Australia, $A, NR
Societal; 2 y of tx;
timeframe NR (PL)
NR NR NR Incremental cost 14 038
Incremental vision-y gained 0.0396
ICER 35 346
Muslera and Natal,[36] Spain, h, NR Healthcare system; 2-y
and lifetime timeframes (no tx)
Median 5 tx
over 2 y
2.5 NR Quality-adjusted cost per visual-acuity life-y gained
Visual acuity maintained for 2 y: women 70 249;
men 66 931
Visual acuity maintained for a lifetime: women (17 y) 7794;
men (13 y) 9743
Smiddy,[32] US, $US, 2006 Third-party payer; 1 y of tx;
lifetime timeframe (no tx)
3.4 in y 1 NR NR Predominantly or minimally classic CNV
Snellen lines saved 1.44; cost per Snellen line-y 448
Occult CNV
Snellen lines saved 1.17; cost per Snellen line-y 551
Smith et al.,[20] UK, X, 2001 Govt and tx costs only;
3 y of tx; 2- and
5-y timeframes (PL)
NR 6.0 (costs);
2.0 (benefits)
2nd eye Incremental cost per vision-y gained
Govt perspective – visual acuity 6/12 (20/40)
2 y 33 645; 5 y 1685
Govt perspective – visual acuity 6/30 (20/100)
2 y 13 877; 5 y 4402
Tx costs only – visual acuity 6/12 (20/40)
2 y 39 826; 5 y 7275
Tx costs only – visual acuity 6/30 (20/100)
2 y 19 977; 5 y 10 180
PG vs UC, no tx or PL
Earnshaw et al.,[21] Canada,
$Can, 2004
Healthcare system; 2 y of tx;
lifetime timeframe (UC)
8.4 in y 1
6.9 in y 2
3 2nd eye Cost: PG 20 016; UC 7669; PL 6737
Vision-y gained: PG 3.83; UC 3.26; PL 2.62
Cost per vision-y gained: 21 559
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Table IV. Contd
Study, country, currency,
y of pricing
Perspective (comparator) No. of tx Annual disc.
rate (%)
Model
type
Outcome measures and results
Javitt et al.,[22] a US, $US, 2006 Third-party payer; 2 y of tx;
lifetime timeframe (UC)
8.4 in y 1
6.9 in y 2
3 2nd eye Early subfoveal CNV
PG: cost 66 638; vision-y gained 5.26
UC: 55 108; vision-y gained 4.50
ICER 15 279
Moderate subfoveal CNV
PG: cost 84 185; vision-y gained 3.75
UC: 71 393; vision-y gained 3.12
ICER 20 350
Late subfoveal CNV
PG: cost 96 771; vision-y gained 0.42
UC: 84 400; vision-y gained 0.21
ICER 57 230
Smiddy,[32] US, $US, 2006 Third-party payer; 1 y of tx;
lifetime timeframe (no tx)
8.3 in y 1 NR NR Cost per Snellen line 12 482
Snellen lines saved 1.04
Cost per Snellen line-y 1248
Wolowacz et al.,[23] UK, X, NR UK Govt; 2 y of tx;
10-y timeframe (BSC)
12.6 over 2 y 3.5 2nd eye PG: cost 28 494; vision-y gained 3.177
BSC: cost 26 111, vision-y gained 2.293
RB vs UC, no tx or PL
Cohen et al.,[37] France, h, 2006 Societal; 1 y of tx;
1-y timeframe (UC)
8 over 1 y NR NR Improvement in visual acuity (>15 letters on ETDRS scale)
RB: cost 9123; success rate 0.488; cost per success
18 721
UC: cost 7604; success rate 0.339; cost per success
22 543
Legal blindness avoided
RB: cost 9196; success rate 0.997; cost per success 9224
UC: cost 5713; success rate 0.931; cost per success 6133
Colquitt et al. (HTA),[2] UK, X, 2005 Healthcare system and
Personal Social Services;
1 y of tx (predominantly classic
CNV); 2 y of tx (minimally
classic CNV); 1- to 2- and
10-y timeframes (BSC)
12 over 1 y
(predominantly
classic CNV);
24 over 2 y
(minimally
classic CNV)
3.5 NR Predominantly classic CNV
RB: 1- to 2-y costs 12 427; vision-y saved 0.98
RB: 10-y costs 26 888; vision-y saved 3.59
BSC: 1- to 2-y costs 933; vision-y saved 0.85
BSC: 10-y costs 20 431; vision-y saved 2.28
Minimally classic or occult with no classic lesions CNV
RB: 1- to 2-y costs 23 902; vision-y saved 1.87
RB: 10-y costs 31 096; vision-y saved 5.19
BSC: 1- to 2-y costs 1541; vision-y saved 1.64
BSC: 10-y costs 13 787; vision-y saved 3.78
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Table IV. Contd
Study, country, currency,
y of pricing
Perspective (comparator) No. of tx Annual disc.
rate (%)
Model
type
Outcome measures and results
Hurley et al.,[26] US, $US, 2004 Societal; third party –
healthcare funder; 4 y of tx;
2- and 10-y timeframes (UC)
12 in y 1
12 in y 2
4 in y 3
4 in y 4
3.0 2nd eye Incremental cost per case of blindness prevented
Including caregiver costs: 2 y 145 400; 10 y dominant
Excluding caregiver costs: 2 y 204 100; 10 y, 217 700
Incremental cost per blind-y prevented
Including caregiver costs: 2 y 116 500; 10 y dominant
Excluding caregiver costs: 2 y 163 500; 10 y 29 200
CADTH (CDR – manufacturer’s
model – HTA),[25] Canada, $Can, 2007
Third-party payer; 1 y of tx
(ANCHOR and PIER);
2 y of tx (MARINA);
10-y timeframe (BSC)
ANCHOR,
PIER or
MARINA
regimen
5.0 2nd eye Predominantly classic CNV
ANCHOR regimen: vision-y gained 2.86 for RB vs 1.81 for
BSC; ICER 5238
PIER regimen: vision-y gained 2.68 for RB vs 1.93 for
BSC; ICER 4166
Minimally classic CNV
Vision-y gained 4.48 for RB vs 3.14 for BSC; ICER 9542
Occult with no classic CNV
Vision-y gained 5.33 for RB vs 4.00 for BSC; ICER 10 345
Regimen Cost
of tx
Snellen
lines
saved
Cost per Snellen line-y
of life expectancy
Smiddy,[38] US, $US, NR Third-party insurer; 2 y of tx;
10-y timeframe (no tx)
22.4 over 2 y NR NR ANCHOR NR 6.2
6.6
474 (1 y)
827 (2 y)
22.4 over 2 y NR NR MARINA NR 3.5
4.3
766 (1 y)
1532 (2 y)
6 over 1 y or
10 over 2 y
NR NR PIER 16 170
26 880
3.2
3.8
505 (1 y)
707 (2 y)
5.6 over 1 y or
9.9 over 2 y
NR NR PrONTO 15 472
21 499
4.4
4.5
344 (1 y)
611 (2 y)
a See table I for study acronyms.
b PG/PDT vs PDT/UC.
$A =Australian dollars; BSC =best supportive care; CADTH =Canadian Agency for Drugs and Technologies in Health; CDR =Common Drug Review; CNV = choroidal
neovascularization; disc. = discount; Govt = government; HTA =health technology assessment; ICER = incremental cost-effectiveness ratio; MSAC =Medical Services Advisory
Committee; NR= not reported; PDT = photodynamic therapy; PG =pegaptanib; PL = placebo; RB = ranibizumab; tx= treatment(s); SwF =Swiss franc; UC= usual care.
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initiation, but was not cost effective for patients
with ‘poor’ initial visual acuity (6/60 [20/200] in
the Australian analysis, 6/30 [20/100] in the UK
analysis). In the UK analysis, PDT was shown to
be cost effective for patients with ‘poor’ initial
visual acuity when indirect costs were included.[20]
Over shorter timeframes (2–3 years), PDT was
not generally shown to be cost effective compared
with best supportive care, as demonstrated by
studies in the UK[18] and Switzerland.[16] Simi-
larly, studies that found PDT to be cost effective
over ‡5 years yielded ICERs considerably above
accepted cost-effectiveness thresholds when time
horizons of 1–2 years were considered.[14,19,20]
2.2.2 Other Cost-Effectiveness Measures
Annual costs for maintaining vision over the
duration of life expectancy were found to be
h7794 per vision-year gained for women (17-year
life expectancy) and h9743 for men (13-year life
expectancy) in Spain.[36] Data from several clinical
trials, along with allowable Medicare amounts
for 2006, were used to determine the cost effec-
tiveness of PDT in the US; costs per Snellen line-
year gained were $US448 for predominantly or
minimally classic CNV and $US551 for occult
CNV.[32]
In Switzerland, two studies evaluated cost ef-
fectiveness in terms of vision-years gained and
calculated costs of h8239-10 271 and Swiss franc
(SwF)9624 per vision-year gained over a 3-year
timeframe.[16,34]
2.3 Pegaptanib
Pegaptanib is a pegylated, modified oligonu-
cleotide that binds to and inhibits VEGF-A.Most
studies that evaluated pegaptanib used data from
the VISION study. VISION demonstrated the abil-
ity of pegaptanib to stabilize the visual acuity of
patients with wet AMD.[7] Summaries of cost-
effectiveness analyses of pegaptanib are presented
in tables III and IV.
2.3.1 Cost Utility
A UK-based analysis by Wolowacz et al.[23]
showed treatment with pegaptanib to be cost ef-
fective relative to best supportive care for sub-
foveal wet AMD over a 10-year timeframe from
a governmental perspective; ICERs were lower
when visual acuity at treatment initiation was
better. However, an HTA by Colquitt et al.[2] cal-
culated higher costs per QALY gained over the
same timeframe and from a similar perspective.
A Canadian study[21] showed pegaptanib to be
‘moderately’ cost effective ($Can20 000–100 000
per QALY gained) compared with usual care
when modelled using VISION efficacy data and a
lifetime timeframe.
In the US, Brown et al.[11] showed that pegapta-
nib treatment of classic subfoveal CNV was ‘mod-
erately’ cost effective (cost per QALY gained
$US50 000–100 000) compared with no treatment
over 12 years. Javitt et al.[22] found pegaptanib to
be cost effective compared with usual care only
when treatment was initiated in the early or mod-
erate stages of disease.
2.3.2 Other Cost-Effectiveness Measures
Data from a number of clinical trials, along
with allowable Medicare amounts for 2006, were
used to determine cost effectiveness of pegaptanib
in the US: cost per Snellen line-year gained was
$US1248.[32] Incremental costs per vision-year
gained varied widely, ranging from d2696 from a
governmental perspective in the UK[23] for all types
of wet AMD, to $US57 230 from a third-party
payer perspective (for late subfoveal CNV).[22]
2.4 Ranibizumab
Ranibizumab is a humanized recombinant
monoclonal antibody fragment directed against
VEGF-A. Ranibizumab inhibits VEGF-A, thereby
preventing endothelial cell proliferation and neo-
vascularization, and slowing progression of wet
AMD. In addition to stabilizing wet AMD, ra-
nibizumab can significantly improve vision: in
two pivotal randomized controlled trials (RCTs),[8,9]
more than 30% of patients with minimally classic
lesions treated monthly with ranibizumab 0.5mg,
and more than 40% of patients with predominantly
classic lesions treated monthly with ranibizumab
0.5mg plus PDT, gained ‡15 letters on the ETDRS
chart within 12 months; this compared with ap-
proximately 5% of those who received sham treat-
ment or sham plus PDT, respectively. Tables III
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and IV summarize the cost-effectiveness outcomes
for ranibizumab compared with usual care, no
treatment or placebo.
2.4.1 Cost Utility
Ranibizumab was found to be cost effective in
Canada, Germany, the UK and the US when out-
comes were viewed over a long-term time horizon
(>10 years). Ranibizumabwas also recommended by
HTAs in Argentina,[39] Australia[40] and Scotland[41]
based on their review of the available economic
evidence. Most of the studies that assessed cost
effectiveness of ranibizumab used data from the
MARINA[9] and ANCHOR[8] studies, where intra-
ocular injections were given on a monthly basis.
However, some studies also investigated alterna-
tive regimens, such as the PIER[42] or PrONTO
regimens,[43] where ranibizumab was administered
less frequently. Notably, HTAs from the UK[2,41]
reported results from the manufacturer’s cost-
effectiveness model, which applied a dosing regi-
men of eight injections in the first year and six
injections in subsequent years, different from those
used in the MARINA and ANCHOR clinical
trials. Importantly, the PrONTO study subse-
quently showed that less frequent dosing was ef-
fective in the majority of patients; ranibizumab
was administered once monthly for 3 months and
then as needed, and a mean of 5.6 injections was
administered per patient over 12 months.[44]
In Germany, Neubauer et al.[27] modelled cost
effectiveness from a societal perspective using visual
acuity data from the MARINA and ANCHOR
clinical studies. Cost effectiveness was determined
separately for the three different fluorescein angio-
graphic subtypes of AMD included in the clinical
studies, and ranibizumab was associated with a cost
per QALY gained of <h30000 for each subtype.[27]
Data from theMARINA study were also used
to model cost effectiveness for minimally classic/
occult CNV in a US setting,[24,26] and ranibizu-
mab was shown to be ‘moderately’ cost effective
from a third-party healthcare provider perspec-
tive over a ‡10-year timeframe. Moreover, in the
analysis by Hurley et al.,[26] ranibizumab was
found to be cost saving compared with usual care
in the US when caregiver costs were taken into
account.
The Canadian Agency for Drugs and Tech-
nologies in Health (CADTH)[25] conducted an
independent economic evaluation of the manu-
facturer’s cost-effectiveness data and concluded
that ranibizumab treatment was cost effective com-
pared with best supportive care if the Product
Listing Agreement (where the manufacturer pays
for additional treatments if patients require more
than nine injections in the first year or more than
six injections in the second and third years) was
implemented.
The cost effectiveness (cost per QALY gained
of <d30 000) of ranibizumab was also demon-
strated by an HTA in the UK for both predomi-
nantly classic CNV (data from the ANCHOR
trial) and minimally classic/occult CNV (data
from the MARINA trial) when costs and bene-
fits, including cost of blindness, were considered
over a 10-year timeframe.[2] A probabilistic sen-
sitivity analysis showed that, for patients with
predominantly classic lesions, ranibizumab had
a probability of being cost effective (compared
with best supportive care) of 95% at a willingness-
to-pay (WTP) threshold of d20 000 per QALY
gained and 99% at a WTP threshold of d30 000
per QALY gained.
2.4.2 Other Cost-Effectiveness Measures
Five studies have evaluated the cost effective-
ness of ranibizumab using measures other than
QALYs. In France, it was concluded that rani-
bizumab was cost effective compared with usual
care when assessed by improvements in visual
acuity modelled over 1 year. The simulation used
efficacy data from a number of published clinical
studies and allowed patients to switch treatments
if they were ineffective. Ranibizumab also re-
duced the rate of legal blindness, although costs
per success for this endpoint were higher than
with usual care.[37] By contrast, Hurley et al.[26]
found ranibizumab to be cost saving compared
with usual care over a 10-year time horizon, when
evaluated by cases of blindness prevented and
blind-years prevented, and viewed from a societal
perspective in the US. HTAs in the UK and
Canada found 2 years of monthly ranibizumab
injections to be associated with incremental costs
per vision-year saved of d12 275 and $Can9542,
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respectively, for minimally classic or occult with
no classic CNV, over a 10-year timeframe; in-
cremental costs for predominantly classic CNV
were d4929 and $Can5238, based on 1 and 2 years
of ranibizumab treatment, respectively.[2,25]
Costs per Snellen line-year of life-expectancy
were found to be $US827, $US1532 and $US707
for the ANCHOR, MARINA and PIER regimens
of ranibizumab treatment, respectively, assuming
2 years of treatment and a 10-year timeframe.[38]
Another alternative ranibizumab regimen used in
the PrONTO study, where injections were given
as needed, was also evaluated and found to cost
$US611 per Snellen line-year of life-expectancy.
3. Comparison of Treatment Options
Studies that compared more than one treatment
option for wet AMD are presented in table III.
In a UK-based HTA, ranibizumab was shown
to be cost effective compared with PDT for pre-
dominantly classic CNV (data from the ANCHOR
trial) over a 10-year time horizon.[2] The CADTH
also showed that ranibizumab was cost effective
compared with pegaptinib, based on 1 year of treat-
ment; cost per QALY gained with ranibizumab
was approximately $Can50 000; that is, at the
commonly accepted cost-effectiveness threshold.[28]
Ranibizumab was cost effective (<h30 000 per
QALY gained) compared with pegaptanib for
minimally classic disease from a societal perspec-
tive in a Spanish setting.[30,31] From a third-party
payer’s perspective, ranibizumab treatment was
slightly above the generally accepted cost-effec-
tiveness threshold when administered according
to the ANCHOR regimen; however, sensitivity
analysis showed that it had a lower cost per QALY
gained (<h5000), well below the cost-effectiveness
threshold, when administered as needed.
Pegaptanib was a cost-effective treatment al-
ternative to PDT for subfoveal wet AMD in
Canada when costs related to wet AMD co-
morbidities were taken into consideration.[21] In
a US study of patients with classic subfoveal
CNV,[11] laser photocoagulation was associated
with a lower cost per QALY ($US8179) than PDT
($US31 544) and pegaptanib ($US66 978). PDT
and pegaptanib improved quality of life (QOL) to
a greater extent; compared with no treatment,
PDT could be considered cost effective (ICER
<$US50 000 per QALY gained) and pegaptanib
treatment could be considered ‘moderately’ cost
effective ($USUS50000–100000 perQALYgained).
In the US,[29] a decision-tree analysis using a
2-year timeframe and a variety of published trial
data for the cost effectiveness of individual wet
AMD therapies relative to best supportive care
showed that ranibizumab was associated with a
lower average cost per QALY than pegaptanib
and PDT when administered using the PIER
regimen (table III). When using the MARINA
regimen, ranibizumab had a lower ICER than
pegaptanib and a similar ICER to PDT; however,
because of the 2-year time horizon employed,
none of the treatments analysed met the gen-
erally accepted threshold for cost effectiveness
($US50 000–100 000 per QALY gained). An ex-
ploratory analysis over 5 years showed the impor-
tance of time horizon, in that the cost per QALY
gained for best supportive care rose markedly as
the proportion of blindness and related costs in-
creased, whereas the cost per QALY gained (and
hence ICER compared with best supportive care)
for ranibizumab, pegaptanib and PDT fell com-
pared with the 2-year assessment.
4. Bevacizumab
Bevacizumab is an anti-VEGF-A antibody li-
censed for the treatment of a number of cancers,
including metastatic colorectal cancer, non-
squamous non-small-cell lung cancer and meta-
static breast cancer. Bevacizumab is not licensed
for the treatment of wet AMD; however, because
its target is the same as ranibizumab and it has a
lower cost once compounded into multiple di-
vided doses from its original oncological dose, it
has been used ‘off-label’ by many physicians.[45,46]
4.1 Cost Utility
There is limited information for evaluating the
cost effectiveness of bevacizumab in wet AMD.
Bevacizumab is often assumed to be more cost
effective than ranibizumab by virtue of its lower
unit cost, but to date, health economic studies
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have not compared the two treatments directly.
As a consequence of the paucity of robust bev-
acizumab clinical data, our review identified no
studies that directly compared the cost utility of
bevacizumab with any other treatment for wet
AMD. HTAs[28,39] that discussed bevacizumab
concluded that there was insufficient evidence to
judge its suitability for the treatment of wet
AMD. Fletcher et al.[29] evaluated the available
data for bevacizumab and estimated a cost per
QALY gained of $US104 748 compared with best
supportive care (the lowest ICER of all com-
parators assessed); however, they did not directly
compare the cost effectiveness of bevacizumab
with other wet AMD therapies because only short-
term efficacy data were available and these were
not from an RCT. The lack of robust compara-
tive RCT data for bevacizumab was also a major
limitation for an exploratory analysis by Raftery
et al.[47] This study projected the cost effective-
ness of bevacizumab relative to ranibizumab for a
range of relative efficacies and determined that,
at the current prices, ranibizumab would have to
provide 2.5-fold greater efficacy than bevacizumab
to be considered cost effective at the generally
accepted threshold of d30 000 per QALY gained.
However, the model used a rather low cost for
bevacizumab (d26 per injection) and by assuming
that the adverse effect profiles of ranibizumab
and bevacizumab were equal, did not take into
account the potential for differences in systemic
adverse events that could affect the relative cost-
effectiveness ratios of these agents.
4.2 Other Cost-Effectiveness Measures
Smiddy[38] used data from several open-label,
non-randomized, uncontrolled treatment studies
and calculated a cost per Snellen line-year of
$US84–107, depending on whether bevacizumab
was administered every 6 weeks, or given as needed.
4.3 Important Considerations for Intraocular
Bevacizumab Use
Off-label use of bevacizumab is controversial
because there is currently little evidence by which
to evaluate its efficacy and long-term safety in the
treatment of wet AMD or other retinal diseases.
Although the recently completed ABC trial has
provided evidence that long-term intravitreal
bevacizumab provides visual acuity improve-
ments superior to standard care for wet AMD
(pegaptanib or PDT) with a low rate of serious
ocular adverse events,[48] there is still relatively
little evidence from robust RCTs – the gold
standard for evaluating the efficacy and safety
of investigational therapies. A recent systematic
review[49] of bevacizumab in the treatment of ocular
neovascular diseases identified 474 studies, of which
nine were RCTs that employed the minimum
methodological rigour necessary to generate robust
data. Furthermore, methodological flaws within
these trials, including potential performance bias
in six of the studies and detection bias in five of
the studies, precluded any definitive conclusions
regarding the safety of intraocular bevacizumab
administration. This lack of safety data makes it
difficult at present to assess the true cost effective-
ness of bevacizumab in wet AMD, at least until the
large, ongoing head-to-head studies report their
findings (expected in 2011–12[50]).
Differences between the bevacizumab and ra-
nibizumab molecules, and their respective for-
mulations, could affect the safety, efficacy and
costs of treatment.[51] Unlike ranibizumab, bev-
acizumab was not designed for use in the eye, and
there is a lack of safety data regarding its intra-
ocular use. Ranibizumab is also formulated to
optimize delivery of the active treatment, while
avoiding potential ocular and systemic complica-
tions. By contrast, bevacizumab is not available
at the small doses needed for intravitreal injec-
tion, and so vials need to be split for use in AMD
if any cost savings are to be made. Splitting vials
in this way may lead to problems maintaining
sterility and potency (as there are no preservatives
in the bevacizumab preparation). There is also a
risk that bevacizumab may contain particulate
matter that could damage the eye, as it is not
manufactured for this use; this is particularly
possible if vials have been repackaged by com-
pounding pharmacies.[52] Finally, the pharmaco-
kinetics and pharmacodynamics of bevacizumab
are different from those of ranibizumab; bev-
acizumab binds more weakly to the VEGF-A
protein, and is a much larger molecule than rani-
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bizumab (149 kDa compared with 48 kDa) with
poorer penetration through the retinal layers.[53]
Animal studies have shown systemic drug ex-
posure to be greater with bevacizumab than ra-
nibizumab, and so concerns have been raised over
the risk of arterio-thromboembolic events.[54-56]
Recently, the French health products safety
agency (AFSSAPS) published an information
sheet[57] recommending caution in the off-label
use of bevacizumab: it highlighted the lack of
safety data on the use of bevacizumab in oph-
thalmology and notes under-notification of ad-
verse effects with the drug. Ocular inflammation,
acute vision loss, and tearing or detachment of the
retinal pigment epithelium are known risks,[58]
and physicians face greater legal responsibility
when prescribing outside a drug licence.[59,60]
5. Other Treatments and Treatment
Combinations
Screening for early AMD and subsequent pro-
phylactic treatment with zinc and antioxidants
was found to be cost effective for delaying and
reducing progression of early AMD in Australia.[61]
If savings from the reduced need for PDT were in-
cluded in the model, costs per QALY gained would
be lower. Themodel assumed optician-based screen-
ing to identify the number of people with early
AMD; outcomes were modelled using data from
AREDS. A US study also found prophylactic zinc
and antioxidants to be cost effective for patients
diagnosed with AMD as assessed by costs per
QALY gained;[62,63] Smiddy[32] calculated costs per
Snellen line-year at $US473 for vitamin therapy.
Smiddy[32,38] also evaluated the cost effective-
ness of various treatment combinations in the US
using data from various clinical trials, and allow-
able Medicare amounts for 2006 or 2008. Triple
therapy with PDT plus corticosteroids plus an
anti-VEGF-A therapy was associated with an
average cost per Snellen line-year of $US71; com-
binations of PDT with intravitreal triamcinolone
or bevacizumab were, on average, slightly more
costly at $US66–269 per Snellen line-year, depend-
ing on how many treatment cycles were assumed,
and what estimates for efficacy were used; and
combination of PDT with ranibizumab was cal-
culated at an average of $US355–6195 per Snellen
line-year, depending on whether treatment was for
1 or 2 years and whether ranibizumab was ad-
ministered on a fixed schedule or given as needed.
6. Health Technology Assessments
Recommendations of formal HTAs consistently
demonstrate that ranibizumab is currently a cost-
effective treatment option for the prevention of
vision loss in wet AMD (table V). Seven HTAs
conducted since 2007 have evaluated ranibizu-
mab, only one of which did not recommend ra-
nibizumab treatment as being cost effective; this
was an assessment in Sweden that did not include
a primary economic analysis and concluded that
the existing literature on cost effectiveness was
insufficient.[64] Of the remaining six, two (from
Scotland and Argentina) were essentially unre-
stricted recommendations.[39,41] The remainder re-
commended use of ranibizumab with conditions
to reduce the overall budget impact; three (from
Canada and the UK) recommended a cap on
the number of reimbursed doses,[2,25,28] and one
(fromAustralia) recommended limitations on pa-
tient subset and prescribing authority.[40] Condi-
tions set on reimbursement allowances were based
on assumptions regarding the number of treat-
ments patients would need and the costs of each
treatment. In the UK, the cap was placed at 14
ranibizumab injections, mostly because the ma-
jority of injections were assumed to be adminis-
tered as surgical day cases rather than outpatient
procedures, thus inflating the costs and pushing
cost effectiveness over the ICER threshold.[2] In
reality, most ranibizumab injections can be car-
ried out in an outpatient setting or in private
ophthalmology rooms, thus making treatment
more cost effective than the HTA determined. As
noted previously, the PrONTO trial subsequently
showed that ranibizumab was effective under a
different treatment regimen involving fewer doses
on average than the regimen assessed in the UK
HTA. All of the HTAs compared ranibizumab
with PDT plus verteporfin; the assessments in the
UK, Canada and Argentina also concluded that
ranibizumab had superior cost effectiveness to
pegaptanib.[2,28,39] In addition to these appraisals,
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Table V. Health technology assessments (HTAs) of treatments (tx) for wet age-related macular degeneration (AMD)
Reference,
country, y
HTA body Treatments
evaluated
Original health
economic
analysis?
Recommendation
Brown et al.,[28]
Canada, 2008
Canadian Agency for Drugs
and Technologies in Health
Ranibizumab
Pegaptanib
PDT with
verteporfin
Bevacizumab
Yes Ranibizumab recommended with dose cap
Ranibizumab is recommended over pegaptanib or PDT as it demonstrates a reversal
of the degenerative process in wet AMD. However, a reduction in list price or dosing
frequency is required to be cost effective at a WTP of $US50 000 per QALY gained;
there is limited clinical trial evidence on the efficacy and safety of bevacizumab in the tx
of AMD
Colquitt et al.,[2]
UK, 2008
National Institute for Health
and Clinical Excellence
Ranibizumab
Pegaptanib
PDT with
verteporfin
Yes Ranibizumab recommended with dose cap
Ranibizumab, within its marketing authorization, is recommended as an option for the
tx of wet AMD up to the cost of 14 injections in the treated eye and with specific
diagnostic criteria; pegaptanib is not recommended for the tx of wet AMD
CDR,[25]
Canada, 2008
Canadian Expert Drug Advisory
Committee
Ranibizumab
PDT with
verteporfin
Yes Ranibizumab recommended with dose cap
Ranibizumab is recommended for the tx of wet AMD when drug plan coverage is
limited to a maximum of 15 vials per pt used to treat the better seeing affected eye
SBU,[64]
Sweden, 2008
SBU Ranibizumab
PDT with
verteporfin
No Further evidence required
Scientific evidence is insufficient to assess the cost effectiveness of ranibizumab in wet
AMD. Monthly tx with ranibizumab improves vision to a substantially higher degree
than PDT in follow-up £2 y
PBAC,[40]
Australia, 2007
PBAC Ranibizumab
PDT with
verteporfin
PL
No Ranibizumab recommended for restricted use
Ranibizumab recommended for tx of subfoveal CNV due to wet AMD as diagnosed by
fluorescein angiography. Initial tx to be prescribed by an ophthalmologist pending
specific authority approval
Augustovski
et al.,[39]
Argentina, 2007
Instituto de Efectividad Clı´nica
y Sanitaria
Ranibizumab
Pegaptanib
Laser
photocoagulation
PDT with
verteporfin
No Ranibizumab recommended
Ranibizumab and pegaptanib are effective for the tx of all wet forms of AMD, and can
be considered as first line. Ranibizumab is superior to pegaptanib as it not only delays
or decreases vision loss, but also causes a great number of pts to have a significant
vision improvement; use of these agents should be limited to subfoveal or juxtafoveal
lesions, where laser photocoagulation is not applicable; there is not adequate evidence
on the usefulness of bevacizumab
SMC,[41]
Scotland, 2007
SMC Ranibizumab
PDT with
verteporfin
No Ranibizumab recommended
Ranibizumab is recommended for the tx of wet AMD. It should be stopped if visual
acuity falls persistently below 6/60 during tx
SMC,[65]
Scotland, 2006
SMC Pegaptanib
PDT with
verteporfin
No Pegaptanib recommended for restricted pt subset
Pegaptanib is recommended for the tx of wet AMD in pts with visual acuity between
6/12 and 6/60 (inclusive) and should be stopped if visual acuity falls below 6/60 during
tx or where severe visual loss is experienced
PBAC,[66]
Australia, 2005
PBAC PDT with
verteporfin
PL
No PDT with verteporfin recommended for restricted pt subset
PDT is recommended for subfoveal CNV secondary to wet AMD where the CNV
comprises predominantly (‡50%) classic lesions as defined by fluorescein
angiography
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Table V. Contd
Reference,
country, y
HTA body Treatments
evaluated
Original health
economic
analysis?
Recommendation
AETMIS,[13]
Canada (QC),
2004
AETMIS PDT with
verteporfin
No tx
Yes PDT with verteporfin recommended for restricted pt subset
PDT is recommended as effective in slowing the progression of subfoveal wet AMD
with predominantly classic CNV or pure occult CNV. The estimated budget impact for
a Que´bec cohort is acceptable if the improvement in QOL is taken into account
Meads et al.,[18]
UK, 2003
National Institute for Health and
Clinical Excellence
PDT with
verteporfin
PL
Yes PDT with verteporfin recommended for restricted pt subset
PDT is recommended for the tx of wet AMD with a confirmed diagnosis of classic with
no occult subfoveal CNV and best-corrected visual acuity 6/60 or better; PDT is not
recommended for the tx of pts with predominantly classic subfoveal CNV associated
with wet AMD
Oliva,[67] Spain
(Catalunya),
2006
Catalan Agency for Health
Technology Assessment and
Research
PDT with
verteporfin
No PDT with verteporfin permitted for restricted pt subset
PDT is recommended for predominantly classic subfoveal CNV and occult CNV with
no classic component caused by AMD and when the neovascular process is active.
Precise and careful pt selection is recommended prior to the tx and when the
neovascular process is active. HR-QOL impact remains to be determined
SBU,[64]
Sweden, 2001
SBU PDT with
verteporfin
No Further evidence required
There is no evidence concerning pt benefits in the long term or the cost effectiveness
of tx. It is important that pts in Sweden are monitored in a uniform way that allows
assessment of the ongoing tx results
MSAC,[35]
Australia, 2001
MSAC PDT with
verteporfin
PL
Yes PDT with verteporfin recommended for restricted pt subset
PDT is recommended only for pts with predominantly classic (>50% classic) subfoveal
CNV secondary to wet AMD
ANAES,[68]
France, 2001
ANAES PDT with
verteporfin
Laser
photocoagulation
Transpupillary
thermotherapy
Surgical tx
External
radiotherapy
No Laser photocoagulation recommended
For the exudative forms of AMD, the tx of choice for perifoveal lesions is laser
photocoagulation; for subfoveal lesions, the only applicable form of tx is PDT when
visual acuity is 2/10 or better
Meads and
Moore[69] UK,
2003
West Midlands Health
Technology Assessment
Collaboration
PDT with
verteporfin
PL
Yes PDT with verteporfin not recommended
PDT with verteporfin was not cost effective for tx of wet AMD; incremental cost per
QALY gained was estimated at £120 095 (estimate range £164 579–79 247) when
taking the cost of blindness into account
AETMIS =Agence D’e´valuation Des Technologies Et Des Modes D’intervention En Sante´; ANAES =National Agency For Accreditation And Evaluation In Health; CDR =Common
Drug Review; CNV = choroidal neovasculariztion; HR-QOL = health-related QOL; MSAC =Medical Services Advisory Committee; PBAC =Pharmaceutical Benefits Advisory
Committee; PDT = photodynamic therapy; PL =placebo; pt = patient(s); QOL =quality of life; SBU =Swedish Council on Technology Assessment in Health Care; SMC =Scottish
Medicines Consortium; WTP =willingness to pay.
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pegaptanib was evaluated separately by the Scot-
tish Medicines Consortium, but was recommend-
ed for use only in a restricted patient subset
(defined by baseline visual acuity).[65] Eight older
HTAs conducted before the availability of rani-
bizumab and pegaptanib were identified for PDT
with verteporfin; of these, five (from Australia,
Canada, Spain and the UK) recommended PDT
only in a restricted patient subset (predominantly
classic CNV, based on the available clinical evi-
dence),[13,18,35,66,67] and the remaining three (from
France, Sweden and theUK) concluded either that
PDT was not cost effective compared with other
options or that further cost-effectiveness evidence
was required.[64,68,69]
7. Discussion
In the Western world, AMD is the leading cause
of severe central vision loss to the point of legal
blindness or worse in people aged ‡50 years.[70,71]
Wet AMD thus has a major impact on patient
QOL and imposes a significant burden on health-
care systems.[72] We conducted a systematic re-
view of studies evaluating the cost effectiveness of
treatments for wet AMD in the published litera-
ture and inHTA reviews, which identified a broad
range of analyses of the most commonly used
therapies for wet AMD (ranibizumab, pegapta-
nib, bevacizumab and PDT with verteporfin),
along with a smaller number of analyses of other
treatments, such as laser photocoagulation and anti-
oxidant vitamins. Although there was considerable
variation in the methodology for cost-effectiveness
modelling across studies, ranibizumab was con-
sistently shown to be a cost-effective therapy for
wet AMD. This finding was supported by the con-
clusions of independently conductedHTA reviews;
of seven identified HTA appraisals that included
ranibizumab, six (including HTA bodies in the
UK, Canada and Australia) recommended that
ranibizumab was cost effective for the treatment
of wet AMD.[2,25,28,39-41]
The majority of published cost-utility analyses
compared ranibizumab, pegaptanib or PDT with
verteporfin with no treatment, usual care or best
supportive care. For ranibizumab, four of the five
studies identified (including HTA appraisals
from the UK and Canada and cost-utility studies
from the US and Germany) showed ranibizumab
to be cost effective depending on time horizon; the
cost-utility studies showed ICERs below commonly
accepted thresholds (e.g. d30 000 or $US50 000
per QALY gained);[2,24,27,37] a fifth study in the
US showed that ranibizumab was dominant over
usual care when caregiver costs were taken into
account, but not cost effective when caregiver
costs were excluded.[26] Of five pegaptanib stud-
ies, oneUK analysis found pegaptanib to be clearly
cost effective versus best supportive care over a
10-year time horizon;[23] the other four studies
(including a UK HTA) showed that the cost
effectiveness of pegaptanib varied considerably
depending on the stage of disease and time hor-
izon.[2,11,21,22] Nine studies provided cost-utility
analyses of PDT with verteporfin compared with
no treatment, usual care or best supportive care,
reflecting that this is an older treatment option
for wet AMD. Over time horizons of ‡5 years,
PDT was shown to be cost effective depending on
model perspective in five studies (two in the US,
two in the UK and one in Canada);[11,13-15,20] two
studies (one in Canada, one in Australia)[17,19]
showed that PDT was of borderline cost effec-
tiveness in patients with good baseline visual
acuity but not cost effective in patients with
greater impairment at baseline; by contrast, two
other studies (a UK HTA analysis and a study
in Switzerland) showed that PDT was not cost
effective.[16,18]
Few published studies have compared active
treatments, but the results of six such studies that
were identified clearly suggested ranibizumab to
be a cost-effective current option for the treat-
ment of wet AMD. Thus, HTA appraisals from
the UK and Canada, and a cost-utility study in
Spain suggested that ranibizumab was cost ef-
fective relative to pegaptanib or PDT with verte-
porfin.[2,28,30,31] The Canadian HTA assessment
and a separate cost-utility study both suggested
that pegaptanib was cost effective relative to PDT
with verteporfin.[21,28] A US study by Fletcher
et al.,[29] comparing the cost effectiveness of all
three treatments with best supportive care, show-
ed a lower ICER for ranibizumab relative to the
other treatments, with PDT having a lower ICER
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than pegaptanib. However, because of the 2-year
time horizon used, all treatments were associated
with ICERs of >$US500 000 per QALY gained,
well in excess of accepted thresholds for cost ef-
fectiveness. This study illustrated clearly the im-
portance of time horizon as a key determinant of
cost effectiveness, as would be expected given
that most wet AMD treatment costs are incurred
in the initial treatment period, whereas benefits
such as avoiding blindness are gained over a con-
siderably longer timeframe. Across the studies
included in this analysis, a time horizon of ‡5 years
was generally necessary to demonstrate cost ef-
fectiveness at standard WTP thresholds of clini-
cally more efficacious, but more expensive, newer
treatments compared with less efficacious, older
options.
In addition to cost-utility analyses, most stud-
ies included one or more of a variety of additional
cost-effectiveness outcomes. The most common
outcome was cost per vision-year saved, although
others (such as cost per Snellen line-year of life-
expectancy and cost per case of blindness pre-
vented) were also evaluated. The absolute costs of
such outcomes are difficult to interpret, and the
variation in methodology, perspective and time
horizon between studies makes cross-study com-
parisons perilous. Nevertheless, the general trend
was for ranibizumab to be more cost effective
than other treatment options. For example, in the
analysis conducted by Smiddy,[32] the calculated
cost per Snellen line-year gained compared with
no treatment over a lifetime in predominantly or
minimally classic CNVwas lowest for ranibizumab
under the PrONTO regimen with 1 year of treat-
ment ($US344); this was lower than the corre-
sponding average values observed for PDT with
verteporfin ($US448) or pegaptanib ($US1248).
It is important to note that the PIER regimen,
where ranibizumab is administered less fre-
quently than with the MARINA and ANCHOR
regimens, was consistently shown to have a lower
cost per QALY gained than the monthly dosing
regimens of MARINA and ANCHOR. How-
ever, mean visual acuity of patients treated using
the PIER regimen is not improved from baseline
after 12 months of treatment, whereas mean vi-
sual acuity is increased using the MARINA or
ANCHOR regimens.[8,9,42] Finding a dosing re-
gimen that maintains the high level of efficacy
seen in the MARINA and ANCHOR studies
while minimizing costs would benefit both pa-
tients and healthcare providers. The PrONTO
study, which used an Optical Coherence Tomo-
graphy-guided variable-dosing regimen, resulted
in visual acuity outcomes similar to theMARINA
and ANCHOR studies, with fewer intravitreal
injections over a 2-year period.[43] Further in-
vestigations will be required to determine whe-
ther this is a cost-effective option.
Almost all of the studies identified in our re-
view utilized a second-eye treatment model for
assessing the cost effectiveness or cost utility of
the treatments under investigation. A second-eye
model is simpler, as it assumes that the first eye
has already lost vision, hence visual acuity bene-
fits are accrued immediately after treatment. By
contrast, a first-eye model presumes that a pa-
tient does not accrue treatment benefit until the
second eye is affected (at which point vision is
deteriorating, and treatment in the first eye
becomes critically important to the patient). A
second-eye model will therefore predict greater
value from treatment than a first-eye model, as
demonstrated by the lower ICERs in studies that
compared both models.[24] On the other hand, a
first-eye model contains more complexity and
uncertainty because it must incorporate model-
ling of progression from unilateral to bilateral
disease. Most clinical studies in wet AMD have
evaluated amixture of first- and second-eye cases,
reflective of clinical practice; the MICMAC ob-
servational study conducted in France, Germany
and Italy showed that the use of laser photo-
coagulation and PDT was similar in first- and
second-eye cases.[73]
The growing off-label use of bevacizumab has
complicated the management of wet AMD. In-
travitreal administration of bevacizumab for wet
AMD remains controversial given the absence of
high-quality, RCT evidence for the comparative
efficacy and long-term safety of this agent relative
to established treatments for wet AMD, such as
ranibizumab. In addition, bevacizumab cost data
are complicated by external and unregulated pric-
ing factors, such as those related to compounding
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pharmacies. As would be expected given the lack
of robust clinical and economic data for bev-
acizumab in this indication, our review identified
no studies that have properly evaluated the cost
effectiveness of bevacizumab in wet AMD. The
available published analyses were based only on
the lower cost of bevacizumab and assumed
equivalent efficacy to ranibizumab. Until rigor-
ous clinical evidence is provided, demonstrating
the comparative efficacy and safety of intravitreal
bevacizumab relative to approved treatments for
wet AMD, it is not appropriate to assume that
bevacizumab would be cost effective compared
with ranibizumab based on the lower acquisition
cost alone. Moreover, while it is hoped that on-
going trials such as CATT[50] and IVAN[74] will
be sufficient to establish the efficacy (and in the
case of IVAN, the safety profile) of bevacizumab
compared with ranibizumab, it is uncertain whe-
ther these outcomes will be adequately shown.
8. Conclusions
Our systematic review finds that ranibizumab
has consistently been shown to be cost effective
for wet AMD in comparison with other currently
approved wet AMD therapies (usual care in-
cluding PDT with verteporfin or pegaptanib), as
judged by the bulk of cost-effectiveness data from
the published scientific literature and supported
by the independent economic assessments of
healthcare providers worldwide. Pegaptanib has
been shown to be of borderline cost effectiveness,
depending on the stage of disease and time hor-
izon. Prior to the launch of VEGF inhibitors,
PDT with verteporfin was recommended as being
a cost-effective option for the treatment of wet
AMD compared with usual/best supportive care
at that time.
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